Valuation: AstraZeneca PLC

Market Cap 272B 429,644B 248B 229B 208B 390B 25,233B 410B 2,783B 1,106B 13,782B 1,022B 1,001B 43,254B P/E 2026 *
23x
P/E 2027 * 19.8x
Enterprise Value 293B 462,491B 267B 246B 224B 420B 27,162B 442B 2,996B 1,191B 14,836B 1,101B 1,077B 46,561B EV / Sales 2026 *
4.63x
EV / Sales 2027 * 4.25x
Free-Float
96.62%
Yield 2026 *
1.9%
Yield 2027 * 2.02%
1 day+4.00%
1 week+2.62%
Current month+2.65%
1 month+14.93%
3 months+19.71%
6 months+13.05%
Current year+12.37%
1 week 75,175
Extreme 75175
79,300
1 month 70,000
Extreme 70000
81,150
Current year 60,650
Extreme 60650
81,150
1 year 60,650
Extreme 60650
81,150
3 years 24,288
Extreme 24288
81,150
5 years 5,438.5
Extreme 5438.5
81,150
10 years 214.5
Extreme 214.5
81,150
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Chief Operating Officer 55 01/06/2015
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+4.00%+2.62% - - 272B
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.70%-4.76%+25.01%+75.64% 452B
Weighted average by Cap. +0.53%-5.19%+26.02%+87.88%

Financials

2026 *2027 *
Net sales 63.38B 99,926B 57.72B 53.19B 48.38B 90.77B 5,869B 95.39B 647B 257B 3,205B 238B 233B 10,060B 67.39B 106,259B 61.38B 56.56B 51.45B 96.52B 6,241B 101B 688B 274B 3,409B 253B 248B 10,698B
Net income 11.69B 18,436B 10.65B 9.81B 8.93B 16.75B 1,083B 17.6B 119B 47.47B 591B 43.87B 42.95B 1,856B 13.59B 21,430B 12.38B 11.41B 10.38B 19.47B 1,259B 20.46B 139B 55.18B 687B 51B 49.92B 2,158B
Net Debt 20.83B 32,847B 18.97B 17.48B 15.9B 29.84B 1,929B 31.36B 213B 84.57B 1,054B 78.16B 76.52B 3,307B 13.65B 21,519B 12.43B 11.45B 10.42B 19.55B 1,264B 20.54B 139B 55.41B 690B 51.21B 50.13B 2,166B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
20/11/26 ARS 79,275.00 +4.00% 298
19/11/26 ARS 76,225.00 -0.85% 534
18/11/26 ARS 76,875.00 -0.36% 724
17/11/26 ARS 77,150.00 -0.42% 128
16/11/26 ARS 77,475.00 +0.29% 205
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
175.69USD
Average target price
215.31USD
Spread / Average Target
+22.55%